CCI clears Torrent Pharma’s acquisition of JB Chemicals
ECONOMY & POLICY

CCI clears Torrent Pharma’s acquisition of JB Chemicals

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties.

The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”.

Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments.

J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services.

The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns.

A detailed order from the Commission will be issued in due course.

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties. The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”. Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments. J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services. The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns. A detailed order from the Commission will be issued in due course.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code